Aljazira Capital, which has initiated coverage on Al Hammadi Development & Investment Co., recommended an “overweight” rating on the stock and set its target price at SAR 56.30.
The decision was based on the company’s expansion plans and a shortage of health care services and facilities in Saudi Arabia, the brokerage firm said in a report.
In addition, Al Hammadi is set to boost its capacity by 340 percent with two new facilities following the opening of Al-Nozha Hospital early next year.
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}